New Zealand Asthma Foundation Launches Campaign to Discourage Youth E-Cigarette Use

Regulations by 2FIRSTS.ai
Dec.26.2023
New Zealand Asthma Foundation Launches Campaign to Discourage Youth E-Cigarette Use
New Zealand Asthma and Respiratory Foundation encourages teenagers to quit e-cigarettes and enjoy the outdoors during the holiday season.

On December 26th, Sun Media, a New Zealand media outlet, reported that the Asthma and Respiratory Foundation New Zealand has launched a campaign during the holiday season to encourage teenagers to quit e-cigarettes. The campaign urges participants to share photos from their outdoor adventures on social media.

 

Foundation CEO Leticia Harding emphasized the importance of finding tranquility outdoors, stating that it does not come from e-cigarettes. She expressed a desire for more young people to fully embrace the peacefulness of the outdoors, particularly during the summer season, prioritizing their health and distancing themselves from e-cigarettes.

 

New Zealand teenage e-cigarette usage has nearly doubled in the past year, according to recent data, raising concerns for the foundation. Letisha emphasized the need to educate teenagers about utilizing their time more effectively, which is the goal of this campaign.

 

Leticia stated that starting from Thursday, the sale of disposable e-cigarettes without batteries, child safety mechanisms, or those that do not comply with the new labeling requirements and contain more than 20 milligrams/milliliters of nicotine will be considered illegal. The forthcoming regulations on e-cigarettes will also assist the foundation in addressing the youth e-cigarette epidemic.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Six Years of Data Show FDA Clearing PMTA Backlog
Six Years of Data Show FDA Clearing PMTA Backlog
FDA data from FY2020 to FY2025 show how the PMTA system for e-cigarette products evolved after an early surge of submissions created prolonged front-end delays. Millions of applications accumulated at the Acceptance stage before entering substantive review. Since 2023, the number of applications pending acceptance has declined sharply, and industry participants report shorter initial decision timelines in late 2025.
Feb.06
UK Court Sentences Shrewsbury Retailer for Illegal Vape and Counterfeit Tobacco Sales
UK Court Sentences Shrewsbury Retailer for Illegal Vape and Counterfeit Tobacco Sales
A UK local authority has secured convictions against a Shrewsbury retailer and its former director for selling illegal disposable vapes, counterfeit tobacco and a nicotine vape to a minor, highlighting continued enforcement against non-compliant nicotine products.
Feb.05 by 2FIRSTS.ai
Vietnam Ho Chi Minh City police seize 28,657 illegal vape-related products worth over US$182,400
Vietnam Ho Chi Minh City police seize 28,657 illegal vape-related products worth over US$182,400
Police in Ho Chi Minh City, Vietnam say they dismantled a large illegal vape distribution ring led by 29-year-old Nguyễn Ngọc Quốc Uy, who allegedly built a concealed “secret room” to hide contraband. Officers seized 28,657 items valued at more than VND 4.8 billion (about US$182,400).
Feb.04 by 2FIRSTS.ai
Japan Tax Reform Threatens JTI Heated Tobacco Growth in 2026
Japan Tax Reform Threatens JTI Heated Tobacco Growth in 2026
Japan’s plan to remove the lower tax rate for heated tobacco products could slow growth in the country’s largest HTP market, JTI’s CFO said. Retail prices may rise by 70 to 100 yen, though the company plans phased increases to soften the impact.
JTI
Feb.15
Denver’s Flavored Tobacco Ban Faces Constitutional Challenge From Vape Trade Group
Denver’s Flavored Tobacco Ban Faces Constitutional Challenge From Vape Trade Group
A Colorado vape industry trade group says Denver’s voter-approved flavored tobacco sales ban is unconstitutional and too vague to enforce. The group is asking a state court for a permanent injunction blocking enforcement of Ordinance 24-1765 and for a declaration allowing flavored tobacco and vape sales, citing state constitutional vagueness concerns and multiple U.S. constitutional issues.
Jan.27 by 2FIRSTS.ai
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11